Skip to main content
. Author manuscript; available in PMC: 2019 May 20.
Published in final edited form as: Sci Signal. 2018 Nov 20;11(557):eaau7632. doi: 10.1126/scisignal.aau7632

Fig. 2. In vivo evaluation of entinostat and vincristine in aRMS patient derived xenograft.

Fig. 2.

(A-H) Graphical analysis of tumor volume inhibition by either ENT alone or in combination with VCR in 8 different PDX aRMS mouse models (Champions Oncology and Jackson Lab) established from clinical biopsies, recurrent aRMS, or autopsies. Demographic features of these models are in tables S3 and S4; treatment schedules are in table S2. Statistical analyses are given in tables S6–S13. (I) Waterfall plot showing tumor growth inhibition (%) for combination treatment (ENT+VCR) in the 8 models shown in panels (A-H), as labeled. (J) Pharmacodynamic assessment of tumor lysates from J77636 treated with ENT for PAX3:FOXO1 protein expression. Blot shows N=3 biological replicates (N represents tumor lysates from 3 mice per cohort).